ImpediMed Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,935.00
14,797.00
25,980.00
27,571.00
27,174.00
Depreciation, Depletion & Amortization
182.00
182.00
184.00
255.00
444.00
Other Funds
662.00
1,744.00
4,877.00
3,178.00
4,041.00
Funds from Operations
7,091.00
12,871.00
20,919.00
24,138.00
22,689.00
Changes in Working Capital
289.00
2,114.00
1,503.00
1,428.00
769.00
Net Operating Cash Flow
6,802.00
10,757.00
22,422.00
25,566.00
23,458.00
Capital Expenditures
32.00
132.00
109.00
362.00
1,215.00
Net Investing Cash Flow
32.00
132.00
109.00
362.00
1,215.00
Net Financing Cash Flow
10,586.00
30,662.00
71,458.00
720.00
256.00
Net Change in Cash
3,496.00
21,770.00
49,672.00
27,370.00
23,539.00
Free Cash Flow
6,834.00
10,889.00
22,531.00
25,901.00
23,613.00
Change in Capital Stock
10,586.00
30,662.00
71,458.00
720.00
256.00
Exchange Rate Effect
256.00
1,997.00
745.00
2,162.00
878.00

About ImpediMed

View Profile
Address
50 Parker Court
Pinkenba Queensland (QLD) 4008
Australia
Employees -
Website http://www.impedimed.com
Updated 07/08/2019
ImpediMed Ltd. engages in the development and distribution of medical devices using bioimpedance spectroscopy technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases. It operates through the Medical and Test and Measurement segments. The Medical segment supplies non-invasive medical devices to two under-served markets: aiding in the subclinical assessment of individuals at risk of secondary lymphoedema; and the monitoring of body composition and hydration.